PCH
KYMR icon

Polar Capital Holdings’s Kymera Therapeutics KYMR Stock Holding History

Polar Capital Holdings’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.9M Buy
215,200
+14,254
+7% +$1.13M 0.06% 153
2025
Q4 		$15.6M Sell
200,946
-196,095
-49% -$13.2M 0.06% 171
2025
Q3 		$22.5M Buy
397,041
+147,041
+59% +$6.63M 0.11% 140
2025
Q2 		$10.9M Buy
+250,000
New +$8.61M 0.06% 185

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Polar Capital Holdings's KYMR Position: Q1 2026 in Review

Polar Capital Holdings increased its Kymera Therapeutics (KYMR) stake by 7.1% in Q1 2026, buying an estimated $1.13M and bringing the position to 215,200 shares worth $17.9M. The position accounts for 0.06% of the portfolio, ranked #153.

Polar Capital Holdings first reported a position in KYMR in Q2 2025 and has held it in 4 quarters since. The position peaked at $22.5M in Q3 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Polar Capital Holdings held 215,200 shares of Kymera Therapeutics worth $17.9M as of Q1 2026.
  • Polar Capital Holdings bought 14,254 Kymera Therapeutics shares in Q1 2026, an estimated $1.13M.
  • Kymera Therapeutics made up 0.06% of Polar Capital Holdings's portfolio in Q1 2026, its #153 holding.
  • Polar Capital Holdings first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Polar Capital Holdings's Kymera Therapeutics position peaked at $22.5M in Q3 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.